Back to journals
Academic JournalOpen Access

Translational Psychiatry

34 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 34 psychedelic papers Blossom tracks from Translational Psychiatry line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Translational Psychiatry carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

9papers published in 2021

+350% vs 2020

16 published by 2021

Browse papers→

Don't read as the journal's total output: only the 34 of 34 tracked psychedelic papers from Translational Psychiatry with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Translational Psychiatry publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
18
Neuroimaging & Brain Measures
15
Anxiety Disorders
7
Microdosing
5
Schizophrenia
5
Addiction & Substance Use
4
Suicidality
4
Creativity
4
Other
15

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Translational Psychiatry cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
12
Ketamine
12
LSD
7
DMT
3
MDMA
3
Mescaline
2

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Translational Psychiatry has 34 tracked papers indexed in Blossom (2014–2026) from 241 authors, most often covering Psilocybin, Ketamine and LSD, across Depressive Disorders, Neuroimaging & Brain Measures and Healthy Volunteers.

Published Papers

Open Accessmeta

Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA

This observational study (n=36) examined blood and saliva samples from clinical trial participants treated with ketamine or MDMA and found changes in DNA methylation across many brain-related genes. The altered genes were linked to neuroplasticity and neuroimmune regulation, suggesting these drugs affect peripheral epigenetic pathways relevant to mental health.

Published
Journal
Translational Psychiatry
Authors
Semple, M. G., Mennenga, S. E., Smith, R., Dwaraka, V. B., Cahn, B. R., Tafur, J., Rabin, D. M., Yazar-Klosinski, B., Lewis, C. R.
Open Accessindividual

High-order brain interactions during ketamine-induced state changes: A functional marker of response in late-life treatment-resistant depression?

This secondary analysis of a randomised, double-blind, midazolam-controlled trial (n=30) examined EEG brain interaction patterns in late-life veterans with treatment-resistant depression after ketamine infusion. Ketamine caused time-dependent changes in these higher-order interactions, and larger 24-hour increases in alpha-band redundancy were linked to greater improvement in depressive symptoms by day 7.

Published
Journal
Translational Psychiatry
Authors
Shah, K., Herzog, R., Swann, A. C., O’Brien, B., Balakrishnan, R., Mathew, S. J., Murphy, N.
Open Accessindividual

Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study

This double-blind, randomised, placebo-controlled crossover study (n=25) in healthy volunteers found that a 60 mg MDMA booster dose given 2 hours after 120 mg MDMA prolonged the subjective drug effects, but did not increase peak effects. Adverse effects were more common after both MDMA conditions than after placebo.

Published
Journal
Translational Psychiatry
Authors
Humbert-Droz, M., Becker, A. M., Valenta, J., Rudin, D., Luethi, D., Vukalovic, I., Eckert, A., Liechti, M. E., Mueller, L.
Open Accessindividual

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder

This longitudinal randomised study (n=37) in detoxified patients with alcohol use disorder examined DNA methylation changes after psilocybin 25 mg versus placebo and found one psilocybin-linked methylation site, plus broader changes related to depression and drinking measures. The changes involved genes and pathways linked to neuroplasticity and immune function.

Published
Journal
Translational Psychiatry
Authors
Urban, M. M., Zillich, L., Rieser, N. M., Herdener, M., Spanagel, R., Vollenweider, F. X., Preller, K. H., Meinhardt, M. W.
Open Accessindividual

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

This double-blind, randomised, placebo-controlled crossover study and separate open-label dose-escalation study (n=36) in healthy participants examined intravenous DMT and found that it produced very strong but short-lived subjective effects, peaking within 2 minutes and fading within 12 to 30 minutes. The strongest effects levelled off at 15 mg, and dose escalation appeared to improve tolerability compared with blinded dosing.

Published
Journal
Translational Psychiatry
Authors
Erne, L., Mueller, L., Straumann, I., Ademaj, B., Eckert, A., Vukalovic, I., Valenta, J., Luethi, D., Liechti, M. E., Vogt, S. B.
Open Accessindividual

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial

In a double-blind randomised trial of patients with long-standing moderate-to-severe depression, two doses of psilocybin plus placebo and six weeks of escitalopram produced comparable reductions in negative affective bias on a facial emotion recognition task at the six-week endpoint. Changes in bias were not associated with concurrent symptom change, although improved recognition of positive faces predicted symptom improvement at week 10 only in the escitalopram group, suggesting partially overlapping but distinct cognitive mechanisms.

Published
Journal
Translational Psychiatry
Authors
Martens, M. A. G., Cunha, B. G., Erritzoe, D., Nutt, D., Carhart-Harris, R., Harmer, C. J.

Quick Facts

Papers Indexed
34
h-Index
137
Open Access
Yes
Publisher
Nature Portfolio
Country
United Kingdom
Website
Visit